0001593968-22-000516.txt : 20220222 0001593968-22-000516.hdr.sgml : 20220222 20220222160953 ACCESSION NUMBER: 0001593968-22-000516 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220218 FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Halpin Michael CENTRAL INDEX KEY: 0001778858 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 22658134 MAIL ADDRESS: STREET 1: C/O VERICEL CORPORATION STREET 2: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2022-02-18 0000887359 Vericel Corp VCEL 0001778858 Halpin Michael C/O VERICEL CORPORATION 64 SIDNEY STREET CAMBRIDGE MA 02139 false true false false Chief Operating Officer Common Stock 2022-02-19 4 M false 2812 0 A 11495 D Common Stock 2022-02-19 4 F false 1248 34.9 D 10247 D Restricted Stock Unit 2022-02-19 4 M false 2812 34.9 D Common Stock 2812 8438 D Stock Option (right to buy) 34.90 2022-02-18 4 A false 2865 0 A 2032-02-18 Common Stock 2865 2865 D Stock Option (right to buy) 34.90 2022-02-18 4 A false 86385 0 A 2032-02-18 Common Stock 86385 86385 D Restricted Stock Unit 2022-02-18 4 A false 15300 0 A Common Stock 15300 15300 D The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. No expiration date for this type of award. These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. /s/ Sean Flynn, as Attorney-in-Fact for Michael Halpin 2022-02-22